EXEL (Exelixis) GF Value : $29.40 (As of Apr. 04, 2025)

View and export this data going back to 2000. Start your Free Trial

What is Exelixis GF Value?

As of today (2025-04-04), Exelixis's share price is $34.57. Exelixis's GF Value is $29.40. Therefore, Exelixis's Price-to-GF-Value for today is 1.18. Based on the relationship between the current stock price and the GF Value, GuruFocus believes Exelixis is Modestly Overvalued.

The GF Value represents the intrinsic value of a stock, determined using GuruFocus' proprietary methodology. The GF Value Line on our stock Summary page provides an estimate of the stock’s fair-trading value.

To calculate this value, GuruFocus follows these steps:

We analyze historical correlations between the stock price and key business performance metrics, such as revenue, earnings, cash flow, and book value.
We identify the metrics that have the strongest historical correlation with the stock price and determine the historical multiples at which the stock has traded relative to these metrics.
Using these historical multiples as a reference, we estimate the stock's fair value while accounting for future business growth. Adjustments may be made based on the company’s past returns and growth trends.

GuruFocus believes that the GF Value Line represents the fair value at which a stock should trade. Stock prices typically fluctuate around this line. If a stock’s price is significantly above the GF Value Line, it is considered overvalued, and its future returns are likely to be lower. Conversely, if the stock price is significantly below the GF Value Line, its future returns are likely to be higher.

Please note that "Possible Value Trap, Think Twice" applies to companies that appear significantly undervalued but are either experiencing a long-term business decline or facing financial distress.

Exelixis (NAS:EXEL) GF Value Explanation

Based on the relationship between the current stock price and the GF Value, GuruFocus provides the following 6 ratings:

Posssible Evaluations	All-in-One Screener Examples (2)
Possible Value Trap, Think Twice (1)	Predictable Companies that possibly be Value Traps
Significantly Overvalued	Predictable Companies which are Significantly Overvalued
Modestly Overvalued	Predictable Companies which are Modestly Overvalued
Fairly Valued	Predictable High Quality Companies which are Fairly Valued
Modestly Undervalued (3)	Predictable High Quality Companies which are Modestly Undervalued
Significantly Undervalued (3)	Predictable High Quality Companies which are Significantly Undervalued

(1) "Possible Value Trap, Think Twice" applies to companies that appear significantly undervalued but are either experiencing a long-term business decline or facing financial distress.

(2) These are some simple examples. You can access our GF Valuation filter under All-in-One Screener’s Fundamental tab, and Price-to-GF-Value filter under Valuation Ratio tab and set your own criteria.

(3) A sufficient margin of safety exists only when the stock is undervalued.

Exelixis's Price-to-GF-Value for today is calculated as

Price-to-GF-Value	=	Share Price	/	GF Value
	=	34.57	/	29.40
	=	1.18

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Exelixis GF Value Related Terms

Thank you for viewing the detailed overview of Exelixis's GF Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Exelixis Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Exelixis Inc (NAS:EXEL) » Definitions » GF Value

Comparable Companies

Traded in Other Exchanges

0IJO:UK EX9:Germany EX9:Germany

Address

1851 Harbor Bay Parkway, Alameda, CA, USA, 94502

Website

https://www.exelixis.com

Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.

Executives

Patrick J. Haley	officer: Sr. Vice President, Commercial	210 EAST GRAND AVE., SOUTH SAN FRANCISCO CA 94080
Jack L Wyszomierski	director	SCHERING PLOUGH CORP, ONE GIRALDA FARMS, MADISON NJ 07940-1000
Julie Smith	director	C/O RAPTOR PHARMACEUTICAL CORP, 9 COMMERCIAL BLVD, SUITE 200, NOVATO CA 94949
Bob Oliver	director	C/O IMMUNOMEDICS, INC., 300 THE AMERICAN ROAD, MORRIS PLAINS NJ 07950
Dana Aftab	officer: CSO/EVP Disc & Trans Research	EXELIXIS, INC., 1851 HARBOR BAY PARKWAY, ALAMEDA CA 94502
Christopher J. Senner	officer: EVP and CFO	210 EAST GRAND AVE., SOUTH SAN FRANCISCO CA 94080
George Poste	director	515 GALVESTON DR, REDWOOD CITY CA 94063
Maria C Freire	director	C/O ALEXANDRIA REAL ESTATE EQUITIES, INC, 26 NORTH EUCLID AVENUE, PASADENA CA 91101
Jeffrey Hessekiel	officer: EVP and General Counsel	210 EAST GRAND AVE., SOUTH SAN FRANCISCO CA 94080
David Edward Johnson	director	590 MADISON AVENUE, NEW YORK NY 10022
Stelios Papadopoulos	director	3 SOMERSET DRIVE SOUTH, GREAT NECK NY 11020
Alan M Garber	director	3355 MILTON COURT, MOUNTAIN VIEW CA 94040
Amy C. Peterson	officer: EVP Prod Dev & Med Aff & CMO	C/O MOURANT OZANNES CORPORATE SERVICES, 94 SOLARIS AVENUE, CAMANA BAY, GRAND CAYMAN E9 KY1-1108
Caligan Partners Lp	director, other: See Remarks	515 MADISON AVENUE, 8TH FLOOR, NEW YORK NY 10022
Tomas J. Heyman	director	C/O AKERO THERAPEUTICS, INC., 170 HARBOR WAY 3RD FLOOR, SOUTH SAN FRANCISCO CA 94080